An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 7, 2002, Pages 443-458

  Moretti, Rita ^a   Torre, Paola ^a   Antonello, Rodolfo M ^a   Cazzato, Giuseppe ^a   Griggio, Stefania ^a   Bava, Antonio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Behavior; Depression; Rivastigmine; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; RIVASTIGMINE;

AFFECTIVE NEUROSIS; AGED; AGGRESSIVENESS; ANXIETY NEUROSIS; ARTICLE; CAREGIVER; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; FUNCTIONAL ASSESSMENT; HALLUCINATION; HUMAN; MALE; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; PARANOIA; PHOBIA; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL SIGNIFICANCE; STRESS; SYMPTOM;

EID: 0036636375     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80050-9     Document Type: Article

References (54)

1. Vascular dementia
2. The prevalence of vascular dementia in Europe: Facts and fragments from 1980-1990 studies
3. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention, and treatment
4. Preventable senility: A call for action against the vascular dementias
5. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers
6. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
7. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia
8. Vascular dementia: Challenge of clinical diagnosis
9. Frontal-subcortical circuits and human behavior
10. Neuropsychological aspects of vascular dementia
11. Differentiation of vascular dementia from AD on neuropsychological tests
12. European pentoxifylline multi-infarct dementia study
13. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R
14. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial
15. Selectivity of cholinesterase inhibition
16. Pathogenesis of vascular dementia in strokeprone spontaneously hypertensive rats
17. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats
18. The neurochemistry of vascular dementia
19. Neurochemical abnormalities in vascular dementia
20. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up
21. Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 22-month study
22. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
23. CT in the differential diagnosis between Alzheimer's disease and vascular dementia
24. Cornell scale for depression in dementia
25. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
26. Impaired awareness of deficits in Alzheimer disease
27. Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats
28. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats
29. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
30. Vascular dementia: Diagnosis, management and possible prevention
31. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial
32. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
33. Results of clinical studies with donepezil in vascular dementia
34. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease
35. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients
36. Improved cortical glucose metabolism in Alzheimer's disease (AD) patients treated with rivastigmine for 1 year
37. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit
38. Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: Differential effects across time
39. Acetylcholinesterase (ACHE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
40. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
41. Rivastigmine in the treatment of parkinsonian hallucinosis
42. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
43. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia
44. Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia
45. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia
46. Symptomatic sinus bradycardia associated with donepezil
47. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
48. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications
49. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
50. Donepezil use in Alzheimer disease